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Abstract
Fosfomycin has emerged as a potential therapy for multidrug-resistant bacterial
infections. In most European countries, the oral formulation is only approved as a
3 g single dose for treatment of uncomplicated cystitis. However, for the treatment
of complicated systemic infections, this dose regimen is unlikely to reach efficacious
serum and tissue concentrations. This study aims to investigate different
fosfomycin-dosing regimens to evaluate its rationale for treatment of systemic
infections. Serum concentration-time profiles of fosfomycin were simulated using a
population pharmacokinetic model based on published pharmacokinetic parameter
values, their uncertainty, inter-individual variability and covariates. The model was
validated on published data and used to simulate a wide range of dosing regimens
for oral and intravenous administration of fosfomycin. Finally, based on the mini-
mum inhibitory concentration for E. coli, surrogate pharmacodynamic indices were
calculated for each dosing regimen. This is the first population pharmacokinetic
model to describe the oral pharmacokinetics of fosfomycin using data from different
literature sources. The model and surrogate pharmacodynamic indices provide quan-
titative evidence that a dosing regimen of 6–12 g per day divided in 3 doses is
required to obtain efficacious exposure and may serve as a first step in the
treatment of systemic multi-drug-resistant bacterial infections.
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1 | INTRODUCTION
Antibacterial resistance remains one of the major threats to human
health, despite its identification as one of the worldwide priority con-
ditions by the WHO over a decade ago.1-3 Particularly alarming is the
rise in number and spread of multi-drug resistant (MDR) bacterial
strains and a poor pipeline of new Gram-negative antibiotics.4-7
To battle MDR bacteria strains, the reassessment and reintroduc-
tion of ‘old’ antibiotics have emerged as alternative solution to cir-
cumvent the long and costly process of developing new
antibiotics.8,9 One of such ‘old’ antibiotics is fosfomycin, developed
more than 40 years ago.10 Fosfomycin is a broad spectrum antibiotic
which exerts its bactericidal activity by irreversibly inhibiting the
early stages of the bacterial cell wall synthesis.11
MDR Gram-negative bacteria are responsible for around two-
thirds of the deaths by MDR-bacterial infections in Europe.6 Fos-
fomycin exhibits in vitro and in vivo antibacterial activity against a
wide range of both Gram-positive and Gram-negative bacteria,
including several MDR-strains.12-17 Even most of the extensively
drug-resistant (XDR) Enterobacteriaceae strains still remain suscepti-
ble to fosfomycin, including those expressing extended-spectrum
beta-lactamases (ESBL) or metallo-b-lactamases (MBL).14-16,18 In
addition, fosfomycin has been suggested as add-on therapy for
infections caused by MDR-P. aeruginosa, one of the main pathogens
associated with nosocomial-acquired infections.16,17,19
Fosfomycin has been marketed in different formulations including
fosfomycin tromethamine for oral administration and fosfomycin dis-
odium for intravenous administration.20 In most European countries,
only the oral formulation is available and approved as a single 3 g dose
for the treatment of uncomplicated urinary tract infections (UTIs) in
women. This single-dose regimen is not efficacious for the treatment
of systemic MDR bacterial infections, making the prospective evalua-
tion of new oral dosing regimens a necessity. A multiple-dose regimen
of oral fosfomycin tromethamine has been proposed for the treatment
of complicated UTIs, including those due to MDR-bacteria.21,22 How-
ever, more studies are urgently needed to determine the optimal oral
dose regimen to achieve efficacious systemic exposure.
Few pharmacokinetic (PK) models for fosfomycin have been
described in literature, which were developed on different study
designs, limited numbers of subjects and different model struc-
tures.23-26 PK modeling techniques allow integration of different
study designs, on the basis that despite study differences the under-
lying population pharmacokinetics are similar, as commonly applied in
dose-regimen selection.27
To assess the feasibility of a multiple oral-dose regimen with fos-
fomycin tromethamine for systemic infections, a combined PK model
for intravenous and oral administration was built on PK parameters
reported in literature in order to simulate various serum-concentra-
tion time profiles. In addition, surrogate pharmacodynamic indices
were calculated, based on the minimum inhibitory concentration
(MIC) representing the epidemiological cut-off value for E. coli,28 to
estimate its clinical efficacy.
2 | METHODS
2.1 | PK model
The structural model for intravenous administration was based on a
previously reported two-compartment population PK model of fos-
fomycin, developed on 12 patients scheduled for abscess drainage.25
The model was parameterized in terms of elimination rate constant
(ke), volumes of distribution for the central (Vc) and peripheral com-
partments (Vp) and intercompartmental clearance (Q). The rate and
duration of infusion were parameterized by Qinf and tinf, respec-
tively.
To include oral administration of fosfomycin tromethamine, the
model was extended with a gastrointestinal- (GI) and a transit com-
ponent (TRANS), based on a PK model published by Segre et al., that
was developed after oral and intravenous administration in 5 healthy
volunteers.24 This model was parameterized in terms of rate con-
stants kij, representing the different rates of drug transfer from the
ith compartment to the jth compartment, including a k10, representing
the first order loss of dose, hence correcting for oral bioavailability.
Additionally, a transfer constant representing biliary clearance of the
drug (kb) was included in the oral PK model. As literature is inconclu-
sive on reabsorption of fosfomycin,24,29,30 models with and without
enterohepatic recirculation were compared to published data in
order to evaluate its descriptive impact on the simulations. The PK
model structures used for the simulations of different multiple-dose
regimens after intravenous and oral administration of fosfomycin are
presented in Figure 1.
F IGURE 1 The two compartment PK model structure used for
the simulations of fosfomycin multiple-dose regimens (black),
together with the excluded enterohepatic recirculation (gray). CL,
clearance; CMT, compartment with associated number; k10, the
first-order loss prior to reaching CMT 2; k12, k23, k56, k61, rate
constants between compartments; kb, biliary elimination; GI;
gastrointestinal; Q, intercompartmental clearance; Qinf infusion rate
constant; tinf, infusion time; TRANS, transit; Vc, central volume of
distribution; Vp, peripheral volume of distribution
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Individual PK parameters were simulated according to Equa-
tion 1.
hi ¼ hTV  exp gið Þ; (1)
where hi is the PK parameter for the i
th individual, hTV the typical
population PK parameter, and gi the interindividual variability (IIV)
for the ith individual.Here, IIV was reported to be log-normally dis-
tributed for CL, Vc, and Vp,25 and incorporated as such in the model;
g is assumed to be normally distributed around 0 with its reported
variance x2.
The hTV is simulated based on literature values of mean popula-
tion PK parameters (hp) and their uncertainty in terms of variance
[based on reported standard deviation (SD) and/or 90% confidence
intervals (CI)], thus resulting in an uncertainty distribution of the
population PK parameter. Both hp and its variance were log-trans-
formed to avoid negative values, according to Equation 2 and Equa-
tion 3.31
hp;LN ¼ lnhp;N  12x
2
LN (2)
x2LN ¼ ln
r2N
h2p;N
þ 1
 !
; (3)
where subscript LN refers to the log domain, and N refers to the nor-
mal domain. Subsequently, hTV was calculated according to Equation
4.
hTV ¼ exp hp;LN þ x2LN
 
(4)
2.2 | Covariates
A mean-centered linear relationship between creatinine clearance
(CLCR) and clearance (CL) was reported,
25 and incorporated as
such in the simulated clearance for the ith individual (CLi, Equa-
tion 5).
CLi ¼ CLTV þ 0:0141  ðCLCR;i  103Þ
    exp gið Þ; (5)
where CLTV is the literature derived mean population parameter with
its uncertainty (Equation 4), CLCR,i is the creatinine clearance and gi
the IIV for the ith individual. The CLCR,i and normalization factor (103)
were obtained from Sauermann et al.32 To simulate CLCR,i, samples
were drawn from a distribution with a mean of 103 and standard
deviation 41, which was limited between the minimal and maximal
reported values.32
2.3 | Simulations
One thousand (1000) individual PK parameter sets (hi) were ran-
domly sampled using the distributions for parameter uncertainty and
IIV, with resampling. The resulting individual PK parameter sets were
then used to simulate individual plasma fosfomycin concentrations
over time. The mean PK parameters, uncertainty and IIV used for
the simulations are listed in Table 1. All simulations were performed
in R (version 2.13.1 33) using the lsoda (deSolve Package 1.10-3) and
mvrnorm functions (MASS Package v7.3-8), within the RStudio34
interface (version 0.98.501).
2.4 | Model validation
The validation of the PK models was performed by simulating previ-
ously published study designs and visually comparing the 90% pre-
diction interval (PI) of the simulations to the observed data reported
in literature. In short, the previously published study designs in
healthy volunteers were, for intravenous administration, 8 doses of
500 mg every 6 hours35; 500 mg in 5 min infusion23; and 50 mg/kg
bolus.24 For single-dose oral administration, dosing regimens were
50 mg/kg, 2 g and 5 g.24
2.5 | Alternative dosing regimens and calculation of
PK/PD indices
Once validated, the different oral dosing regimens were simulated to
assess the feasibility of a multiple dosing regimen. These scenarios
included the simulation of total daily doses ranging from 3 g to 45 g
once or divided into two or three times per day for oral fosfomycin
tromethamine.
PK parameters were obtained in R and included: maximum serum
concentration (Cmax), time to reach Cmax (Tmax), area under the serum
concentration–time curve (linear trapezoidal rule with 0.1 h
TABLE 1 Pharmacokinetic parameter values used in the
simulations
Parameter
Mean estimate
(90% CI or SD) IIV
Uncertainty
(variance)a Reference
CL (L/h)b 5.808 (3.792–7.80) 0.238 1.4841 Kjellsson
et al.25
Vc (L) 10.1 (5.36–14.8) 0.238*1.64 8.2329 Kjellsson
et al.25
Vp (L) 9.80 (5.70–13.9) 0.197 6.2120 Kjellsson
et al.25
Q (L/h)b 15.36 (9.12–21.6) NI 14.3892 Kjellsson
et al.25
COVCLCR-CL 0.0141 – –
k10 (h
1) 1.24  0.55 ND 0.3025 Segre
et al.24
k12 (h
1) 1.69  0.62 ND 0.3844 Segre
et al.24
k23 (h
1) 0.34  0.10 ND 0.0100 Segre
et al.24
kb (h
1) 0.50  0.18 ND 0.0324 Segre
et al.24
CL, clearance; Vc, volume of distribution of central compartment; Vp, vol-
ume of distribution of peripheral compartment; Q, intercompartmental
clearance; COVCLCR-CL
, linear relationship between creatinine clearance
and CL; kx,y, rate constants from compartment x to y; NI, not identified;
kb, rate constant biliary elimination; ND, no data available.
aCalculated from the 90% CI or SD.
bValue converted to match units.
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time-steps) over the dosing interval (AUC0-tau), and AUC from time 0
to time of the last simulated concentration (AUC0-last).
Surrogate pharmacodynamic indices were based on the minimum
inhibitory concentration (MIC) of 8 mg/L, as this represents the epi-
demiological cut-off value for E. coli according to EUCAST 28 and
include: Cmax/MIC, AUC/MIC, time above MIC (T>MIC) and percent-
age of T>MIC during the dose interval (%T>MIC). Primarily, the mean
estimated values of Cmax and AUC during 24 hour at steady state
were used. The Cmax/MIC and %T>MIC were calculated over the
length of a dose interval at steady state, while AUC/MIC was calcu-
lated over a period of 24 hours at steady state as defined by Mou-
ton et al.36 Secondly, the lower 90% prediction interval (PI) of the
simulated plasma concentration-time profiles was used, e.g., 95% of
all subjects will have higher exposure compared to this PI.
3 | RESULTS
3.1 | PK Models
The contribution of enterohepatic recirculation on improvement of
descriptive properties of the model proved to be marginal; the med-
ian concentrations and 90% PI did not differ substantially. The slight
changes were considered to be of no clinical relevance. Secondly, as
there is also no consistent proof for enterohepatic recirculation in lit-
erature, it was decided to exclude this PK property from the model.
The parameter kb was kept in the model as this rate constant for
apparent biliary elimination is required to attest for the total elimina-
tion of fosfomycin.
All observations following intravenous (Figure 2) and oral dosing
(Figure 3) lie within the 90% PI of the PK model. For the intravenous
simulations, Cmax is well described and the median slope of the terminal
elimination phase follows the slope of the data. However, the terminal
elimination phase and trough concentrations seem overpredicted by
the model. Following the multiple 500 mg dose in 8 hours dosing inter-
vals, no accumulation occurs and the simulated median concentration
remains above the MIC until approximately 5 hours after dosing. For
the oral simulations, the median Cmax seems well predicted although
the shape of the concentration-time curve in the terminal phase
seems steeper compared to the data. Following the single 50 mg/kg
dose, the simulated median serum concentration remains above the
MIC until approximately 10 hours after dosing. As all data points lie
within the 90% PI of the simulations, the PI is wider than expected
based on the data, indicating that the variability of the model is
overestimated.
3.2 | Simulation of different multiple-dose regimens
and calculation of PK/PD Indices
Different multiple-dose regimens after oral administration of fos-
fomycin were simulated using the validated PK model. Figure 4
shows the medians of the predicted PK profiles of 1000 subjects
after intravenous administration of 3, 4, 6, or 8 g of fosfomycin
every 8 hours by 30 min infusion, as well as the MIC. In addition,
simulation of different dosing schedules such as 4 g and 6 g every
6 hours were also conducted (data not shown). All simulated intra-
venous regimens reached serum concentrations above the MIC. The
surrogate pharmacodynamic indices and mean PK measures for each
dosing regimen are shown in Table 2. All intravenous dosing regi-
mens simulated produced Cmax levels of at least 18-fold over the
MIC, AUC/MIC values from 180 to 500, and a 100%T>MIC.
Several oral dose regimens were simulated for doses of 3 g and
6 g of fosfomycin tromethamine, including a single dose per day
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F IGURE 2 Mean plasma fosfomycin concentration-time profiles
(black line) and 90% prediction interval (gray area) of 1000 simulated
subjects with observations (circles): (A) simulations and data after
1 minute iv bolus injection of 50 mg/kg fosfomycin disodium24; (B)
simulations after 500 mg of fosfomycin disodium in a 5-10 minute
short iv infusion with data (blue; data obtained by Kwan et al.,23 red;
data obtained by Cadorniga35). The dashed line represents the
minimum inhibitory concentration
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(qd), two times daily (bid) and three times daily (tid). The predicted
medians of these different dose regimens as presented in Figure 5
show that the medians of all first doses reached serum
concentrations above the MIC. For both dose groups, concentrations
only maintain above the MIC for the entire duration of the day fol-
lowing tid dosing. As shown in Table 3, a 2 g tid dose would also
not suffice to reach a %T>MIC of 100%. Interestingly, the currently
clinically approved 3 g single oral dose for UTIs may achieve effica-
cious concentrations in urine, however, it only achieves a %T>MIC of
around 30% in serum. Although most of the regimens reached a high
%T>MIC, comparable to the intravenous regimens, the Cmax/MIC and
AUC/MIC values are lower than those in intravenous regimens: the
Cmax/MIC is 17.78 after 15 mg bid and the AUC/MIC values range
from 37 to 300. Table 3 also represents the pharmacodynamic
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F IGURE 3 Mean serum fosfomycin
concentration-time profiles (black line) and
90% prediction interval (gray area) of 1000
simulated subjects with reported
observations24 after oral administration of
fosfomycin tromethamine: (A) 50 mg/kg
with data (blue circles,24 (B) 2 g with
reported mean values  SD and (C) 5 g
with reported mean values  SD. The
dashed line represents the minimum
inhibitory concentration
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F IGURE 4 Median serum fosfomycin concentration-time profiles
of 1000 simulated subjects after three times daily (tid) iv bolus
dosing of 3, 4, 6 and 8 mg fosfomycindisodium. Horizontal dashed
line represents the minimum inhibitory concentration
TABLE 2 Mean surrogate pharmacodynamic indices for different
intravenous dosing regimens of fosfomycin disodium, using a MIC of
8 mg/L
Dose (g)
Interval
(h)
Cmax
(mg/L) Cmax/MIC
AUC
(mg/L*h)
AUC/
MIC8 %T>MIC
3 8 151.41 18.93 1490.82 186.35 100
4 8 201.88 25.24 1987.76 248.47 100
4 6 224.04 28.00 2684.44 335.55 100
6 8 302.83 37.85 2981.64 372.70 100
6 6 336.05 42.01 4026.66 503.33 100
8 8 403.77 50.47 3975.52 496.94 100
Cmax, maximum concentration; MIC, minimum inhibitory concentration;
AUC, area under the concentration-time curve; %T>MIC, time above the
MIC during a dose interval, expressed as percentage.
ORTIZ ZACARIAS ET AL. | 5 of 8
indices based on the lower 90% PI of the plasma concentration-time
simulations. These results show that for some individuals, a minimum
dose of 4 g tid will be required in order to reach a Cmax that exceeds
the MIC, and remains above the MIC for more than 50% of the dose
interval.
4 | DISCUSSION
This is the first population PK model to describe the oral pharma-
cokinetics of fosfomycin, using data from different literature sources.
The study provides quantitative evidence that an oral dosing regi-
men of 6–12 g per day divided in 3 doses is required to obtain
serum concentrations above the MIC for at least 50% of the dose
interval. This may serve as a first step in the treatment of systemic
infections by MDR bacteria with a similar MIC compared to E.coli.
Model validation showed a slight bias in the description of litera-
ture data and overprediction of variability. The slight bias can be
explained by the use of few subjects in the development of the liter-
ature models causing relatively high parameter uncertainty and IIV,
which accumulates in large prediction intervals. Following intra-
venous simulation, late PK time points seem overestimated while for
oral simulations time points after 15 hours seem underestimated,
which may lead to bias in accumulation following multiple dosing
regimens. In general, the reported population PK parameters used in
our simulations were within the CI reported in a recent publication
on intravenous fosfomycin infusion in critically ill patients. Compared
to the volume of distribution in our simulations, the publication
reports a relatively high volume of distribution, which the authors
attest to pathophysiological changes in their critically ill patient pop-
ulation.26 We acknowledge the quantitative and qualitative lack of
data in literature, which is the case for many drugs that have been
developed in the past. For this reason, we stress the importance of
additional clinical data to ascertain whether oral fosfomycin may be
used for the treatment of systemic.
The suggested daily oral doses of fosfomycin tromethamine to
achieve an effective serum concentration exceed the currently
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F IGURE 5 Median serum concentration-time profiles of
fosfomycin simulated in 1000 subjects following oral administration
of 3 or 6 g of fosfomycintromethamine with various dose regimens:
single dose (sd), two times daily (bid) or three times daily (tid).
Dashed blue line represents the minimum inhibitory concentration of
8 mg/L
TABLE 3 Surrogate pharmacodynamic indices based on the median (med) and lower limit of the 90% prediction interval (90PI) PK
simulations for different oral dosing regimens of fosfomycin tromethamine, using a MIC of 8 mg/L
Dose(g) Interval(h) Cmax (mg/L) med/90PI Cmax/MIC med/90PI AUC (mg/L*h) med/90PI AUC/MIC med/90PI %T>MIC med/90PI
2 8 18.96/5.16 2.37/0.65 316.95/92.18 39.62/11.52 84/0
3 8 28.44/7.75 3.56/0.97 475.42/138.26 59.43/17.28 100/0
3 12 24.52/6.60 3.07/0.82 313.48/88.52 39.19/11.06 66/0
3 24 22.87/6.05 2.86/0.76 154.26/41.58 19.28/5.20 31/0
4 8 37.93/10.33 4.74/1.29 633.89/184.35 79.24/23.04 100/51.57
5 8 47.41/12.91 5.93/1.61 792.36/230.44 99.05/28.80 100/67.63
6 8 56.89/15.50 7.11/1.94 950.84/276.53 118.85/34.57 100/78.75
6 12 47.70/13.34 5.96/1.67 602.87/178.67 75.36/22.33 87/45.76
6 24 44.12/12.12 5.51/1.52 296.83/83.11 37.10/10.39 42/20.44
7 8 66.37 8.30 1109.31 138.66 100
8 8 75.85 9.48 1267.78 158.47 100
9 8 85.33 10.67 1426.26 178.28 100
10 8 94.81 11.85 1584.73 198.09 100
11 8 104.30 13.04 1743.20 217.90 100
12 8 113.78 14.22 1901.67 237.71 100
15 8 142.22 17.78 2377.09 297.14 100
Cmax, maximum concentration; MIC, minimum inhibitory concentration; AUC, area under the concentration–time curve; %T>MIC, time above the MIC
during a dose interval, expressed as percentage.
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approved single dose of 3 g. To our knowledge, safety and tolerabil-
ity has not been investigated in vivo, using higher oral doses. Alter-
native approaches to avoid such higher doses when dealing with
systemic MDR infections may lie in synergistic combinations with
other antibiotics, such as imipenem for treatment of methicillin-resis-
tent Staphylococcus aureus,37 or approval of intravenous fosfomycin
formulations. Yet, more studies are urgently needed to assess the
PK, safety, tolerability, and efficacy of fosfomycin in multiple-dose
regimens and synergistic combinations.
The broad range of daily doses suggested with these simulations
(from 6 up to 12 g per day) can be explained, in part, by the rela-
tively large parameter uncertainty and IIV reported in literature. To
our knowledge, serum creatinine clearance is the only reported
covariate in literature that explains part of the IIV. In addition, dis-
ease state may explain IIV of volume of distribution.26 These aspects
contribute to wide prediction intervals around the means of the sim-
ulations. An effect of bodyweight on volume of distribution has been
used in a study but was not statistically supported.26 Inclusion of
more data and demographics would reduce the parameter uncer-
tainty and improve quantitation of the IIV and is anticipated to pro-
vide a more precise prediction interval. With the current available
literature data, the current dosing results based on the lower 95%
prediction interval may prove to be a relatively conservative
approach.
In this study, different surrogate pharmacodynamic indices were
used to evaluate the effect of different dose regimens on the epi-
demiological cut-off value for E. coli. However, an important limita-
tion in the evaluation of different dose regimens and optimization of
therapy is the lack of information regarding the PD properties of
fosfomycin. Few studies have attempted to characterize the PD
properties of fosfomycin, but results are conflicting. Some studies
pointed to a time-dependent bactericidal activity,38,39 while others
have suggested a concentration-dependent bactericidal activity.40
This again stresses the need for more data.
The lack of PD data has also affected the clinical and PD break-
points for MDR-bacterial infections from a regulatory perspective. In
the case of fosfomycin tromethamine, the EUCAST has established
clinical breakpoints for Enterobacteriaceae (Susceptible ≤32 mg/L
and Resistant > 32 mg/L) which are only applicable to uncompli-
cated UTIs caused by Enterobacteriaceae, using a single dose of
3 g.28 As clinical breakpoints depend on the clinical features of the
disease and the dose regimen, we chose the epidemiological cut-off
value of fosfomycin for E. coli to calculate the PD indices. This value
is independent of the dose regimens and exclusively determined by
the MIC values distribution and therefore not used to advise on clin-
ical therapy.41 In this regard, further studies are urgently needed to
establish the PK–PD relationships of fosfomycin. Microbiological sus-
ceptibility information could also be included in Monte Carlo simula-
tions in order to define oral dosing regimens based on potential PK/
PD targets with high probability of microbiological cure. This has
been recently reported following intravenous infusion of fosfomycin in
the treatment of Klebsiella pneumoniae,42 and Pseudomonas aeruginosa.43
Literature review on fosfomycin PK and simulations clearly indi-
cate the need for further clinical research to characterize the PK and
PD properties of fosfomycin tromethamine. Previous studies
reported potential decreased absorption at higher doses 24,44 and
fosfomycin recirculation.24 In the model building, these concepts
were considered but did not improve the descriptive properties of
the model with regards to the available data. Also, when administer-
ing doses that are higher than the current recommended dose in the
clinic, this may result in nonlinear PK.24,44 Hence, in the design of a
future clinical trial, dose regimens as well as sampling times should
be chosen to optimally address these potential PK characteristics.
Characterization of these processes is the key to the design of opti-
mal multiple-dose strategies, as saturable absorption or elimination
can limit the use of higher doses and recirculation can lead to clini-
cally relevant accumulation.
Simulations and PD indices show that a total daily oral dose of
at least 6–12 g of fosfomycin tromethamine are required to achieve
a therapeutic concentration to treat systemic infections, based on
the epidemiological cut-off value for E. coli. In light of the reported
simulations, the population PK model can be used to optimize a new
clinical trial to assess the PK, safety, and tolerability of fosfomycin
tromethamine in multiple-dose regimens.
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